uniQure N.V. (NASDAQ:QURE) shares skyrocketed on Monday following news that Dr. Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research (CBER), will resign in April.

The Momentum Paradox

The stock jumped 26.07%, closing with significant gains as investors bet that his departure would ease the regulatory path for the company's Huntington's disease gene therapy, AMT-130.

Despite the massive single-day rally, Benzinga Edge’s Stock Rankings tell a more complex story. The stock's momentum score cratered week-on-week, falling from a robust 93.8 to a mere 28.01.

This ranking, which measures price strength and volatility relative to the broader market, reflects the heavy toll of recent months. Even with Monday’s surge, QURE remains down 24.82% Year-to-Date, highlighting a long-term downward ...